Interleukin-10 and the pathogenesis of human visceral leishmaniasis

Trends in Immunology

Volumn 28, Issue 9, 2007, Pages 378-384

  Nylén, Susanne ^a   Sacks, David ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; ANTIMONY DERIVATIVE; GAMMA INTERFERON; INTERLEUKIN 10; MESSENGER RNA; MILTEFOSINE; PAROMOMYCIN;

ANTIGEN SPECIFICITY; B LYMPHOCYTE ACTIVATION; CELL POLARITY; CORRELATION ANALYSIS; DISEASE COURSE; HOMEOSTASIS; HUMAN; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; INFECTION SENSITIVITY; LEISHMANIA; LOW DRUG DOSE; NONHUMAN; PATHOGENESIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; REVIEW; TH1 CELL; VISCERAL LEISHMANIASIS;

ANIMALS; HUMANS; INTERLEUKIN-10; LEISHMANIA DONOVANI; LEISHMANIA INFANTUM; LEISHMANIASIS, VISCERAL;

EID: 34548543615     PISSN: 14714906     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.it.2007.07.004     Document Type: Review

References (94)

1. Sundar S., and Rai M. Advances in the treatment of leishmaniasis. Curr. Opin. Infect. Dis. 15 (2002) 593-598
2. Bacellar O., et al. Interleukin-12 restores interferon-γ production and cytotoxic responses in visceral leishmaniasis. J. Infect. Dis. 173 (1996) 1515-1518
3. Bacellar O., et al. IL-10 and IL-12 are the main regulatory cytokines in visceral leishmaniasis. Cytokine 12 (2000) 1228-1231
4. Caldas A., et al. Balance of IL-10 and interferon-γ plasma levels in human visceral leishmaniasis: implications in the pathogenesis. BMC Infect. Dis. 5 (2005) 113
5. Engwerda C.R., et al. Neutralization of IL-12 demonstrates the existence of discrete organ-specific phases in the control of Leishmania donovani. Eur. J. Immunol. 28 (1998) 669-680
6. Ghalib H.W., et al. IL-12 enhances Th1-type responses in human Leishmania donovani infections. J. Immunol. 154 (1995) 4623-4629
7. Murray H.W., et al. Killing of intracellular Leishmania donovani by lymphokine-stimulated human mononuclear phagocytes. Evidence that interferon-γ is the activating lymphokine. J. Clin. Invest. 72 (1983) 1506-1510
8. Squires K.E., et al. Experimental visceral leishmaniasis: role of endogenous IFN-γ in host defense and tissue granulomatous response. J. Immunol. 143 (1989) 4244-4249
9. Carvalho E.M., et al. Immunologic markers of clinical evolution in children recently infected with Leishmania donovani chagasi. J. Infect. Dis. 165 (1992) 535-540
10. Sacks D.L., et al. An analysis of T cell responsiveness in Indian kala-azar. J. Immunol. 138 (1987) 908-913
11. Garg R., et al. Immunostimulatory cellular responses of cured Leishmania-infected patients and hamsters against the integral membrane proteins and non-membranous soluble proteins of a recent clinical isolate of Leishmania donovani. Clin. Exp. Immunol. 140 (2005) 149-156
12. White Jr. A.C., et al. Leishmania chagasi antigens recognized in cured visceral leishmaniasis and asymptomatic infection. Am. J. Trop. Med. Hyg. 46 (1992) 123-131
13. + (Foxp3) regulatory T cells in human visceral leishmaniasis. J. Exp. Med. 204m (2007) 805-817
14. + cells and IL-2 production in the peripheral blood of patients with visceral leishmaniasis. J. Immunol. 146 (1991) 1026-1030
15. Babaloo Z., et al. Interleukin-13 in Iranian patients with visceral leishmaniasis: relationship to other Th2 and Th1 cytokines. Trans. R. Soc. Trop. Med. Hyg. 95 (2001) 85-88
16. Sundar S., et al. Circulating T helper 1 (Th1) cell- and Th2 cell-associated cytokines in Indian patients with visceral leishmaniasis. Am. J. Trop. Med. Hyg. 56 (1997) 522-525
17. Thakur C.P., et al. Skewing of cytokine profiles towards T helper cell type 2 response in visceral leishmaniasis patients unresponsive to sodium antimony gluconate. Trans. R. Soc. Trop. Med. Hyg. 97 (2003) 409-412
18. Ansari N.A., et al. Elevated levels of interferon-γ, interleukin-10, and interleukin-6 during active disease in Indian kala azar. Clin. Immunol. 119 (2006) 339-345
19. de Medeiros I.M., et al. Presence of circulating levels of interferon-γ, interleukin-10 and tumor necrosis factor-α in patients with visceral leishmaniasis. Rev. Inst. Med. Trop. Sao Paulo 40 (1998) 31-34
20. Kurkjian K.M., et al. Multiplex analysis of circulating cytokines in the sera of patients with different clinical forms of visceral leishmaniasis. Cytometry A 69 (2006) 353-358
21. Milano S., et al. IL-15 in human visceral leishmaniasis caused by Leishmania infantum. Clin. Exp. Immunol. 127 (2002) 360-365
22. Ghalib H.W., et al. Interleukin 10 production correlates with pathology in human Leishmania donovani infections. J. Clin. Invest. 92 (1993) 324-329
23. Karp C.L., et al. In vivo cytokine profiles in patients with kala-azar. Marked elevation of both interleukin-10 and interferon-γ. J. Clin. Invest. 91 (1993) 1644-1648
24. Kenney R.T., et al. Splenic cytokine responses in Indian kala-azar before and after treatment. J. Infect. Dis. 177 (1998) 815-818
25. Kaye P.M., et al. The immunopathology of experimental visceral leishmaniasis. Immunol. Rev. 201 (2004) 239-253
26. Sanchez M.A., et al. Organ-specific immunity in canine visceral leishmaniasis: analysis of symptomatic and asymptomatic dogs naturally infected with Leishmania chagasi. Am. J. Trop. Med. Hyg. 70 (2004) 618-624
27. Mohamed H.S., et al. SLC11A1 (formerly NRAMP1) and susceptibility to visceral leishmaniasis in The Sudan. Eur. J. Hum. Genet. 12 (2004) 66-74
28. Bucheton B., et al. Identification of a novel G245R polymorphism in the IL-2 receptor β membrane proximal domain associated with human visceral leishmaniasis. Genes Immun. 8 (2007) 79-83
29. Hughes S., and Kelly P. Interactions of malnutrition and immune impairment, with specific reference to immunity against parasites. Parasite Immunol. 28 (2006) 577-588
30. Anstead G.M., et al. Malnutrition alters the innate immune response and increases early visceralization following Leishmania donovani infection. Infect. Immun. 69 (2001) 4709-4718
31. Hassan M.F., et al. The Schistosoma mansoni hepatic egg granuloma provides a favorable microenvironment for sustained growth of Leishmania donovani. Am. J. Pathol. 169 (2006) 943-953
32. O'Neal S.E., et al. Influence of helminth infections on the clinical course of and immune response to Leishmania braziliensis cutaneous leishmaniasis. J. Infect. Dis. 195 (2007) 142-148
33. Jeronimo S.M., et al. An emerging peri-urban pattern of infection with Leishmania chagasi, the protozoan causing visceral leishmaniasis in northeast Brazil. Scand. J. Infect. Dis. 36 (2004) 443-449
34. Shiddo S.A., et al. Visceral leishmaniasis in Somalia: prevalence of markers of infection and disease manifestations in a village in an endemic area. Trans. R. Soc. Trop. Med. Hyg. 89 (1995) 361-365
35. Liu L., et al. Testosterone attenuates p38 MAPK pathway during Leishmania donovani infection of macrophages. Parasitol. Res. 99 (2006) 189-193
36. Murray H.W., et al. Visceral leishmaniasis in mice devoid of tumor necrosis factor and response to treatment. Infect. Immun. 68 (2000) 6289-6293
37. Bassetti M., et al. Visceral leishmaniasis infection in a rheumatoid arthritis patient treated with adalimumab. Rheumatology (Oxford) 45 (2006) 1446-1448
38. Fabre S., et al. Visceral leishmaniasis infection in a rheumatoid arthritis patient treated with infliximab. Clin. Exp. Rheumatol. 23 (2005) 891-892
39. Romani-Costa V., et al. Visceral leishmaniasis related to infliximab administration. Enferm. Infecc. Microbiol. Clin. 22 (2004) 310
40. Karplus T.M., et al. Association between the tumor necrosis factor locus and the clinical outcome of Leishmania chagasi infection. Infect. Immun. 70 (2002) 6919-6925
41. Ato M., et al. Defective CCR7 expression on dendritic cells contributes to the development of visceral leishmaniasis. Nat. Immunol. 3 (2002) 1185-1191
42. Lundqvist A., et al. Mature dendritic cells induce tumor-specific type 1 regulatory T cells. J. Immunother. 28 (2005) 229-235
43. Mege J.L., et al. The two faces of interleukin 10 in human infectious diseases. Lancet Infect. Dis. 6 (2006) 557-569
44. Moore K.W., et al. Interleukin-10 and the interleukin-10 receptor. Annu. Rev. Immunol. 19 (2001) 683-765
45. Lowe P.R., et al. Influence of interleukin-10 polymorphisms on interleukin-10 expression and survival in critically ill patients. Crit. Care Med. 31 (2003) 34-38
46. Shin H.D., et al. Genetic restriction of HIV-1 pathogenesis to AIDS by promoter alleles of IL10. Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 14467-14472
47. Nelson D.R., et al. Long-term interleukin 10 therapy in chronic hepatitis C patients has a proviral and anti-inflammatory effect. Hepatology 38 (2003) 859-868
48. Murphy M.L., et al. IL-10 mediates susceptibility to Leishmania donovani infection. Eur. J. Immunol. 31 (2001) 2848-2856
49. Murray H.W., et al. Determinants of response to interleukin-10 receptor blockade immunotherapy in experimental visceral leishmaniasis. J. Infect. Dis. 188 (2003) 458-464
50. Vouldoukis I., et al. Interleukin-10 and interleukin-4 inhibit intracellular killing of Leishmania infantum and Leishmania major by human macrophages by decreasing nitric oxide generation. Eur. J. Immunol. 27 (1997) 860-865
51. Wu J., et al. IL-10 inhibits the synthesis of migration inhibitory factor and migration inhibitory factor-mediated macrophage activation. J. Immunol. 151 (1993) 4325-4332
52. Honstettre A., et al. Dysregulation of cytokines in acute Q fever: role of interleukin-10 and tumor necrosis factor in chronic evolution of Q fever. J. Infect. Dis. 187 (2003) 956-962
53. Carvalho E.M., et al. Restoration of IFN-γ production and lymphocyte proliferation in visceral leishmaniasis. J. Immunol. 152 (1994) 5949-5956
54. Cenini P., et al. Mononuclear cell subpopulations and cytokine levels in human visceral leishmaniasis before and after chemotherapy. J. Infect. Dis. 168 (1993) 986-993
55. Colovai A.I., et al. Flow cytometric analysis of normal and reactive spleen. Mod. Pathol. 17 (2004) 918-927
56. Hailu A., et al. T cell subset and cytokine profiles in human visceral leishmaniasis during active and asymptomatic or sub-clinical infection with Leishmania donovani. Clin. Immunol. 117 (2005) 182-191
57. + T cells during Leishmania donovani infection. Eur. J. Immunol. 35 (2005) 498-504
58. Shevach E.M. From vanilla to 28 flavors: multiple varieties of T regulatory cells. Immunity 25 (2006) 195-201
59. + regulatory T cells control Leishmania major persistence and immunity. Nature 20 (2002) 502-507
60. + T cells in skin lesions of patients with cutaneous leishmaniasis exhibit phenotypic and functional characteristics of natural regulatory T cells. J. Infect. Dis. 193 (2006) 1313-1322
61. Roncarolo M.G., et al. Type 1 T regulatory cells. Immunol. Rev. 182 (2001) 68-79
62. + T cells. Eur. J. Immunol. 36 (2006) 1764-1771
63. Anderson C.F., et al. CD4(+)CD25(-)Foxp3(-) Th1 cells are the source of IL-10-mediated immune suppression in chronic cutaneous leishmaniasis. J. Exp. Med. 204 (2007) 285-297
64. Jankovic D., et al. Conventional T-bet(+)Foxp3(-) Th1 cells are the major source of host-protective regulatory IL-10 during intracellular protozoan infection. J. Exp. Med. 204 (2007) 273-283
65. Gerosa F., et al. Interleukin-12 primes human CD4 and CD8 T cell clones for high production of both interferon-γ and interleukin-10. J. Exp. Med. 183 (1996) 2559-2569
66. Accapezzato D., et al. Hepatic expansion of a virus-specific regulatory CD8(+) T cell population in chronic hepatitis C virus infection. J. Clin. Invest. 113 (2004) 963-972
67. Peruhype-Magalhaes V., et al. Mixed inflammatory/regulatory cytokine profile marked by simultaneous raise of interferon-γ and interleukin-10 and low frequency of tumour necrosis factor-α(+) monocytes are hallmarks of active human visceral leishmaniasis due to Leishmania chagasi infection. Clin. Exp. Immunol. 146 (2006) 124-132
68. Holaday B.J., et al. Potential role for interleukin-10 in the immunosuppression associated with kala azar. J. Clin. Invest. 92 (1993) 2626-2632
69. Hailu A., et al. Distinct immunity in patients with visceral leishmaniasis from that in subclinically infected and drug-cured people: implications for the mechanism underlying drug cure. J. Infect. Dis. 184 (2001) 112-115
70. Elshafie A.I., et al. Circulating immune complexes (IC) and IC-induced levels of GM-CSF are increased in Sudanese patients with acute visceral Leishmania donovani infection undergoing sodium stibogluconate treatment: implications for disease pathogenesis. J. Immunol. 178 (2007) 5383-5389
71. Galvao-Castro B., et al. Polyclonal B cell activation, circulating immune complexes and autoimmunity in human American visceral leishmaniasis. Clin. Exp. Immunol. 56 (1984) 58-66
72. Mary C., et al. Characterization of a circulating antigen involved in immune complexes in visceral leishmaniasis patients. Am. J. Trop. Med. Hyg. 49 (1993) 492-501
73. Sousa-Atta M.L., et al. Immunoglobulin E antileishmanial antibody response in cutaneous leishmaniasis. Clin. Diagn. Lab. Immunol. 9 (2002) 101-104
74. Rizos E., et al. Cryoglobulinemic purpura in visceral leishmaniasis. Rheumatol. Int. 25 (2005) 469-471
75. Veress B., and el Hassan A.M. Vascular changes in human leishmaniasis: a light microscope and immunohistological study. Ann. Trop. Med. Parasitol. 80 (1986) 183-188
76. Duarte M.I., et al. Interstitial nephritis in human kala-azar. Trans. R. Soc. Trop. Med. Hyg. 77 (1983) 531-537
77. Kumar P.V., et al. Leishmania in the glomerulus. Arch. Pathol. Lab. Med. 128 (2004) 935-936
78. Miles S.A., et al. A role for IgG immune complexes during infection with the intracellular pathogen Leishmania. J. Exp. Med. 201 (2005) 747-754
79. Smelt S.C., et al. B cell-deficient mice are highly resistant to Leishmania donovani infection, but develop neutrophil-mediated tissue pathology. J. Immunol. 164 (2000) 3681-3688
80. Buxbaum L.U., and Scott P. Interleukin 10- and Fcγ receptor-deficient mice resolve Leishmania mexicana lesions. Infect. Immun. 73 (2005) 2101-2108
81. Kima P.E., et al. Internalization of Leishmania mexicana complex amastigotes via the Fc receptor is required to sustain infection in murine cutaneous leishmaniasis. J. Exp. Med. 191 (2000) 1063-1068
82. Kane M.M., and Mosser D.M. The role of IL-10 in promoting disease progression in leishmaniasis. J. Immunol. 166 (2001) 1141-1147
83. + T lymphocyte cell death in human immunodeficiency virus infection and AIDS. J. Gen. Virol. 84 (2003) 1649-1661
84. Georgescu L., et al. Interleukin-10 promotes activation-induced cell death of SLE lymphocytes mediated by Fas ligand. J. Clin. Invest. 100 (1997) 2622-2633
85. + lymphocyte subset and monocyte apoptosis in patients with acute visceral leishmaniasis. Immunology 113 (2004) 260-268
86. Alexander C.E., et al. CD95 is required for the early control of parasite burden in the liver of Leishmania donovani-infected mice. Eur. J. Immunol. 31 (2001) 1199-1210
87. Eidsmo L., et al. Alteration of Fas and Fas ligand expression during human visceral leishmaniasis. Clin. Exp. Immunol. 130 (2002) 307-313
88. Dash S., et al. Haematological profile of childhood visceral leishmaniasis. Indian J. Pathol. Microbiol. 48 (2005) 4-6
89. Marwaha N., et al. Clinico-hematological characteristics in patients with kala azar. A study from north-west India. Trop. Geogr. Med. 43 (1991) 357-362
90. Veress B., et al. Morphology of the spleen and lymph nodes in fatal visceral leishmaniasis. Immunology 33 (1977) 607-610
91. Murray H.W., et al. Antagonizing deactivating cytokines to enhance host defense and chemotherapy in experimental visceral leishmaniasis. Infect. Immun. 73 (2005) 3903-3911
92. Llorente L., et al. Clinical and biologic effects of anti-interleukin-10 monoclonal antibody administration in systemic lupus erythematosus. Arthritis Rheum. 43 (2000) 1790-1800
93. + T cells express both type 1 cytokines and interleukin-10. Scand. J. Immunol. 57 (2003) 291-295
94. Cillari E., et al. in vivo and in vitro cytokine profiles and mononuclear cell subsets in Sicilian patients with active visceral leishmaniasis. Cytokine 7 (1995) 740-745